Loading
Life sciences · Journal article
Journal of Emergency Medicine · November 1, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background Medetomidine, a highly potent α₂-adrenergic agonist veterinary sedative, has emerged as an adulterant in the unregulated opioid supply, producing a distinct spectrum of intoxication and withdrawal that poses new challenges for emergency clinicians. Objective To summarize the epidemiology, pharmacology, diagnosis, clinical features, and emergency department management of medetomidine intoxication and withdrawal. Methods We conducted a narrative review of PubMed/MEDLINE from database inception through October 10, 2026, supplemented by reference-list review. Peer-reviewed human studies, toxicologic surveillance reports, relevant pharmacologic and veterinary studies, governmental and public health reports, prescribing information, and clinical guidance were included when pertinent to emergency care. Discussion Acute medetomidine intoxication is characterized by profound central nervous system depression, marked bradycardia, and variable blood pressure abnormalities, often in the setting of fentanyl co-exposure. Routine hospital toxicology screens do not detect medetomidine, making diagnosis primarily clinical and dependent on local epidemiology. Management is supportive, with naloxone directed toward concomitant opioid-induced respiratory depression. Withdrawal can produce severe autonomic hyperactivity with hypertension, tachycardia, agitation, nausea, and vomiting and may require oral α₂-agonists or intravenous dexmedetomidine, along with treatment of concurrent opioid withdrawal. No reversal agent is approved for medetomidine intoxication in humans; atipamezole remains investigational. Conclusions Emergency clinicians should recognize both intoxication and withdrawal, provide syndrome-directed supportive and α₂-agonist therapy, and incorporate harm reduction and addiction treatment while evidence continues to evolve.